ReviewJournal of experimental & clinical cancer research : CR2009
Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review.
Review in Journal of experimental & clinical cancer research : CR, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Efficacy and safety of target combined chemotherapy in advanced gastric cancer: a meta-analysis and system review.BMC cancer · 2016Pooled it
- Berry-derived Bioactive Compounds as Chemopreventive Agents in Colorectal Cancer: Molecular Mechanisms and Gut Microbiota Interactions.Journal of cancer prevention · 2026Review
- Generation of CCR4/CD7 Bispecific CAR-T Cells Resistant to Fratricide and Exhaustion.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- Review
- Bronchoalveolar lavage as a diagnostic procedure: a review of known cellular and molecular findings in various lung diseases.Journal of thoracic disease · 2020Review
- Anticancer therapy and lung injury: molecular mechanisms.Expert review of anticancer therapy · 2018Review
- Interstitial lung disease secondary to Cetuximab in bladder cancer: an Oncologist's perspective.BMJ case reports · 2017Article
- A case of fatal cetuximab-induced interstitial lung disease during the first weeks of treatment.Targeted oncology · 2014Article
- Epidermal growth factor receptor and metastatic colorectal cancer: insights into target therapies.World journal of gastroenterology · 2013Review
- Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses.Oncoimmunology · 2013Review
- A rare but severe pulmonary side effect of cetuximab in two patients.BMJ case reports · 2012Review
- Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets.British journal of pharmacology · 2012Review
- Infectious complications in head and neck cancer patients treated with cetuximab: propensity score and instrumental variable analysis.PloS one · 2012Article
- Article
- Review
- Chromogenic in situ hybridization to detect EGFR gene copy number in cell blocks from fine-needle aspirates of non small cell lung carcinomas and lung metastases from colo-rectal cancer.Journal of experimental & clinical cancer research : CR · 2010Article
- Neck emphysema in a HNSCC cancer patient undergoing concurrent radiotherapy and cetuximab.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation OncologyArticle
- Update on the role of imaging in management of metastatic colorectal cancer.Radiographics : a review publication of the Radiological Society of North America, IncReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Compounds derived from biologic sources, or biologicals, are increasingly utilized as therapeutic agents in malignancy. Development of anti-cancer targeted therapies from biologics is increasingly being utilized. Cetuximab, a chimeric monoclonal antibody, is one such anti-cancer targeted therapeutic that has shown efficacy in quelling the rate of patient decline in colorectal, head/neck, and non-small cell lung cancer. However, due to the relatively recent addition of biologic compounds to the therapeutic arsenal, information related to adverse reactions is less well known than those seen in traditional chemotherapeutics. Dermatologic reactions have been demonstrated as the most frequent side effect cited during cetuximab therapy for malignancy; however, other effects may lead to greater morbidity. In general, pulmonary complications of therapeutics can lead to significant morbidity and mortality. The purpose of this review is to compile the various pulmonary side effects seen in patients treated with cetuximab for various malignancies, and to compare the incidence of these adverse reactions to standard therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.